BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock
$9.40
Price · Aug 19, 2026
Fundamentals as of Aug 11, 2026
52W Range
$7–$15
30% of range
Analyst Rating
BUY
17 analysts
Price Target
$25
+167% upside
P/E (TTM)
-2.2
ROE
-146.2%
Net Profit Margin
—
BBOT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$9.40
Market Cap
$752M
P/E (TTM)
-2.2
EPS (TTM)
$-4.30
Revenue (TTM)
—
Div Yield
—
ROE
-146.2%
Debt/Equity
0.0
52W Range
$7 – $15
BBOT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
$-4.30
2024-12-31
→
2025-12-31
Free Cash Flow
$-114M
2025-12-31
→
2025-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
BBOT
Peer Median
P/E (TTM)
-2.2
70.4
P/B
1.8
2.2
EV / EBITDA
-2.2
—
Price / FCF
-6.6
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
BBOT
Peer Median
ROA
-43.8%
-35.6%
ROE
-146.2%
-37.4%
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
BBOT
Peer Median
Debt / Equity
0.0
—
Current Ratio
12.3
7.1
Quick Ratio
12.1
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
BBOT
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
BBOT
Peer Median
BBOT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
17 analysts
- Strong Buy 6 35.3%
- Buy 10 58.8%
- Hold 1 5.9%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
10 analysts · 2026-08-15
Median
$23.50
← Below all targets
$9.40
Low
$18.00
High
$39.00
Median target
$23.50
+150.0%
Mean target
$25.10
+167.0%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.20%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.53 | $-0.54 | 0.01% |
| Dec. 31, 2025 | $-0.49 | $-0.53 | 0.04% |
| Sept. 30, 2025 | $-1.03 | $-0.40 | -0.63% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BBOT | $1.00B | -2.9 | — | — | -146.2% | — |
| ACHV | — | -4.0 | — | — | — | — |
| CTMX | $725M | — | -44.8% | -22.8% | -15.9% | — |
| NGNE | $319M | -4.9 | — | — | -33.6% | — |
| STTK | $231M | -5.2 | -82.5% | -4880.9% | -70.0% | — |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | — |
| IRWD | $550M | 22.5 | -15.7% | 8.1% | -8.5% | — |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | — |
| ALLO | $314M | -1.6 | -76.8% | — | -59.9% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 13
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $121M | $73M | · | |
| SG&A Expense | $25M | $8M | $41.7K | |
| Operating Expenses | $146M | $81M | · | |
| Operating Income | $-146M | $-81M | $-41.7K | |
| Interest Income | $11M | $6M | · | |
| Other Non-op | $-35.0K | $0 | · | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-134M | $-74M | $-41.7K | |
| EPS (Basic) | $-4.30 | $-5756.41 | · | |
| EPS (Diluted) | $-4.30 | $-5756.41 | · | |
| Shares (Basic) | 31,144,775 | 12,903 | · | |
| Shares (Diluted) | 31,144,775 | 12,903 | · | |
| EBITDA | $-146M | $-584.4K | · |
Balance Sheet 21
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $374M | $31M | $0 | |
| Short-term Investments | $52M | $125M | · | |
| Prepaid Expense | $7M | $3M | · | |
| Current Assets | $432M | $159M | · | |
| PP&E (Net) | $956.0K | $490.0K | · | |
| Other Non-current Assets | $13M | $5M | · | |
| Total Assets | $448M | $164M | $332.9K | |
| Accounts Payable | $1M | $3M | · | |
| Accrued Liabilities | · | $119.7K | $15.0K | |
| Short-term Debt | $534.0K | $483.0K | $70.1K | |
| Current Liabilities | $35M | $20M | $396.5K | |
| Capital Leases | $2M | $0 | · | |
| Total Liabilities | $37M | $20M | $396.5K | |
| Total Debt | $534.0K | · | · | |
| Common Stock | $8.0K | $0 | · | |
| Paid-in Capital | $768M | $44M | $24.5K | |
| Retained Earnings | $-357M | $-223M | $-88.6K | |
| AOCI | $16.0K | $348.0K | · | |
| Stockholders' Equity | $411M | $-179M | $-116M | |
| Liabilities + Equity | $448M | $164M | $332.9K | |
| Shares Outstanding | 79,991,768 | 28,415 | · |
Cash Flow 9
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | · | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-114M | $-55M | · | |
| CapEx | $606.0K | $49.0K | · | |
| Investing Cash Flow | $73M | $-121M | · | |
| Stock Issued | $112M | · | · | |
| Net Stock Activity | $112M | · | · | |
| Financing Cash Flow | $383M | $206M | · | |
| Free Cash Flow | $-114M | · | · |
Profitability 2
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -43.8% | 7.8% | · | |
| ROE | -146.2% | -9.3% | · |
Liquidity & Solvency 3
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 12.3 | 10.4 | · | |
| Quick Ratio | 12.1 | 9.1 | · | |
| Debt / Equity | 0.0 | · | · |
Valuation (TTM) 11
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-134M | $-74M | · | |
| Market Cap | $1.00B | · | · | |
| Enterprise Value | $577M | · | · | |
| P/E | -2.9 | -0.0 | · | |
| P/B | 2.4 | · | · | |
| P / Tangible Book | 2.4 | · | · | |
| P / Cash Flow | -8.8 | · | · | |
| P / FCF | -8.7 | · | · | |
| EV / EBITDA | -4.0 | · | · | |
| EV / FCF | -5.0 | · | · | |
| Earnings Yield | -34.4% | -54823.0% | · |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $40M | $38M | $35M | $27M | $21M | $20M | $18M | · | · | |
| SG&A Expense | $11M | $6M | $7M | $14M | $3M | $3M | $6M | $2M | $152.3K | $66.7K | |
| Operating Expenses | $60M | $46M | $43M | $49M | $30M | $23M | $22M | $20M | · | · | |
| Operating Income | $-60M | $-46M | $-93M | $-49M | $-30M | $-23M | $-61M | $-20M | $-152.3K | $-66.7K | |
| Interest Income | $4M | $4M | $4M | $3M | $2M | $2M | $255.2K | $2M | $2M | $1M | |
| Other Non-op | $-14.0K | $-94.0K | $-4M | $-30.0K | $-8.0K | $-2.0K | $-4M | $0 | $2M | $1M | |
| Income Tax | $0 | · | $0 | $0 | $0 | $0 | $0 | $0 | · | · | |
| Net Income | $-56M | $-42M | $-39M | $-45M | $-28M | $-22M | $-20M | $-17M | $-22M | $-15M | |
| EPS (Basic) | $-705.20 | $-526.11 | $2.19 | $-1.03 | $-566.46 | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| EPS (Diluted) | $-705.20 | $-526.11 | $2.19 | $-1.03 | $-566.46 | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| Shares (Basic) | 80,054,000 | 80,032 | 16,459,785 | 43,491,085 | 50,198,000 | 406,723 | 1,814 | 11,089 | · | · | |
| Shares (Diluted) | 80,054,000 | 80,032 | 16,459,785 | 43,491,085 | 50,198,000 | 406,723 | 1,814 | 11,089 | · | · | |
| EBITDA | $-60M | $-46M | · | $-49M | $-1M | $-2M | · | $-146.9K | $-152.3K | $-66.7K |
Balance Sheet 21
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $53M | $374M | $409M | $664.2K | $963.1K | $31M | $2M | $2M | $2M | |
| Short-term Investments | $172M | $200M | $52M | $60M | · | · | $125M | · | · | · | |
| Prepaid Expense | $16M | $14M | $7M | $7M | $62.5K | · | $3M | · | $11.3K | $16.3K | |
| Current Assets | $242M | $267M | $432M | $476M | $876.8K | $1M | $159M | $2M | $2M | $2M | |
| PP&E (Net) | $878.0K | $938.0K | $956.0K | $827.0K | · | · | $490.0K | · | · | · | |
| Other Non-current Assets | $13M | $11M | $13M | $5M | · | · | $5M | · | · | · | |
| Total Assets | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Accounts Payable | $7M | $12M | $1M | $4M | $3M | · | $3M | · | · | · | |
| Accrued Liabilities | · | · | · | · | · | $2M | · | $126.7K | $79.1K | $23.3K | |
| Short-term Debt | · | $716.0K | $534.0K | $691.0K | · | · | $483.0K | · | · | · | |
| Current Liabilities | $52M | $43M | $35M | $36M | $3M | $2M | $20M | $126.7K | $79.1K | $23.3K | |
| Capital Leases | $2M | $2M | $2M | $2M | · | · | $0 | · | · | · | |
| Total Liabilities | $54M | $45M | $37M | $38M | $8M | $7M | $20M | $6M | $6M | $6M | |
| Total Debt | · | $716.0K | · | $691.0K | · | · | · | · | · | · | |
| Common Stock | $8.0K | $8.0K | $8.0K | $8.0K | · | · | $0 | · | · | $51 | |
| Paid-in Capital | $779M | $772M | $768M | $764M | · | · | $44M | · | · | · | |
| Retained Earnings | $-455M | $-399M | $-357M | $-318M | $-7M | $-6M | $-223M | $-4M | $-3M | $-3M | |
| AOCI | $-959.0K | $-981.0K | $16.0K | $36.0K | · | · | $348.0K | · | · | · | |
| Stockholders' Equity | $323M | $372M | $411M | $447M | $-7M | $-6M | $-179M | $-4M | $-3M | $-3M | |
| Liabilities + Equity | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Shares Outstanding | 80,115,002 | 80,088,931 | 79,991,768 | 79,196,710 | · | · | 28,415 | · | · | · |
Cash Flow 8
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $4M | $3M | $3M | $36.0K | $627.0K | $4M | $77.4K | $77.4K | $39.4K | |
| Operating Cash Flow | $-44M | $-36M | $-42M | $-71M | $-298.9K | $-20M | $-15M | $-39M | $-29.1K | $-618.0K | |
| CapEx | $47.0K | $24.0K | $73.0K | $140.0K | $231.0K | $162.0K | $10.0K | · | · | · | |
| Investing Cash Flow | $46M | $-285M | $8M | $41M | $10M | $15M | $26M | $38M | $0 | $-184M | |
| Stock Issued | $0 | $112M | $-9M | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $112M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $37.0K | $295.0K | $-586.0K | $365M | $19M | $-404.0K | $52.0K | $20M | $0 | $186M | |
| Free Cash Flow | · | $-36M | · | · | · | · | · | · | · | · |
Profitability 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -19.7% | -13.7% | · | -13.2% | 0.47% | -0.25% | · | 2.4% | 2.3% | 1.2% | |
| ROE | -35.8% | -23.0% | · | -20.2% | -17.2% | 10.4% | · | -132.7% | -131.2% | -68.3% |
Liquidity & Solvency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 6.2 | · | 13.3 | 0.3 | 0.7 | · | 16.1 | 26.2 | 90.4 | |
| Quick Ratio | 4.4 | 5.8 | · | 13.1 | 0.3 | 0.5 | · | 14.1 | 22.9 | 79.0 | |
| Debt / Equity | · | 0.0 | · | 0.0 | · | · | · | · | · | · |
Valuation (TTM) 11
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-172M | $-137M | · | $-113M | $-90M | $-77M | · | · | · | · | |
| Market Cap | $610M | $717M | · | $917M | · | · | · | · | · | · | |
| Enterprise Value | · | $465M | · | $450M | · | · | · | · | · | · | |
| P/E | -0.0 | · | · | · | · | · | · | · | · | · | |
| P/B | 1.9 | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Tangible Book | 1.9 | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Cash Flow | · | -20.0 | · | · | · | · | · | · | · | · | |
| P / FCF | · | -19.9 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | · | -10.1 | · | -9.1 | · | · | · | · | · | · | |
| EV / FCF | · | -12.9 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -23606.3% | · | · | · | · | · | · | · | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Net Income | $-134M | $-74M | $-41.7K |
| Diluted EPS | $-4.30 | $-5756.41 | — |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Debt / Equity | 0.0 | — | — |
| Current Ratio | 12.3 | 10.4 | — |
| Quick Ratio | 12.1 | 9.1 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Free Cash Flow | $-114M | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 65 filers · $429.4M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 20 (+3 vs prior Q) | 17 (+10 vs prior Q) | 16 (-3 vs prior Q) | 14 (+3 vs prior Q) | +2.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Cormorant Asset Management, LP | $136,234,886 | 17,878,594 | 31.73% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $37,227,099 | 4,885,446 | 8.67% | Shares |
| Omega Fund Management, LLC | $25,067,217 | 3,289,661 | 5.84% | Shares |
| Alphabet Inc. | $21,512,220 | 2,823,126 | 5.01% | Shares |
| EcoR1 Capital, LLC | $21,512,220 | 2,823,126 | 5.01% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $21,254,481 | 2,789,302 | 4.95% | Shares |
| ENAVATE SCIENCES GP, LLC | $20,017,329 | 2,626,946 | 4.66% | Shares |
| CITADEL ADVISORS LLC | $19,269,166 | 2,528,762 | 4.49% | Shares |
| NOVO HOLDINGS A/S | $17,145,000 | 2,250,000 | 3.99% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $15,283,045 | 2,005,649 | 3.56% | Shares |
| Laurion Capital Management LP | $15,260,582 | 2,002,701 | 3.55% | Shares |
| ARMISTICE CAPITAL, LLC | $13,441,680 | 1,764,000 | 3.13% | Shares |
| STATE STREET CORP | $7,898,656 | 1,036,569 | 1.84% | Shares |
| Aisling Capital Management LP | $7,757,297 | 1,018,018 | 1.81% | Shares |
| Opaleye Management Inc. | $5,334,000 | 700,000 | 1.24% | Shares |
| Granahan Investment Management, LLC | $4,255,968 | 558,526 | 0.99% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $3,918,497 | 513,932 | 0.91% | Shares |
| SPHERA FUNDS MANAGEMENT LTD. | $3,512,706 | 460,985 | 0.82% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $3,048,000 | 400,000 | 0.71% | Shares |
| ROYCE & ASSOCIATES LP | $2,933,250 | 384,941 | 0.68% | Shares |
| Catalio Capital Management, LP | $2,426,261 | 318,407 | 0.57% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,221,398 | 291,522 | 0.52% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,183,267 | 286,518 | 0.51% | Shares |
| Casdin Capital, LLC | $2,151,217 | 282,312 | 0.50% | Shares |
| Ensign Peak Advisors, Inc | $2,084,299 | 273,530 | 0.49% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $1,872,418 | 244,441 | 0.44% | Shares |
| FMR LLC | $1,833,235 | 240,582 | 0.43% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,456,578 | 191,152 | 0.34% | Shares |
| NORTHERN TRUST CORP | $1,230,493 | 161,482 | 0.29% | Shares |
| Sio Capital Management, LLC | $995,385 | 130,628 | 0.23% | Shares |
| UBS Group AG | $873,671 | 114,655 | 0.20% | Shares |
| MILLENNIUM MANAGEMENT LLC | $803,758 | 105,480 | 0.19% | Shares |
| GOLDMAN SACHS GROUP INC | $777,888 | 102,085 | 0.18% | Shares |
| MOORE CAPITAL MANAGEMENT, LP | $762,000 | 100,000 | 0.18% | Shares |
| Brevan Howard Capital Management LP | $690,714 | 88,895 | 0.16% | Shares |
| Palumbo Wealth Management LLC | $652,455 | 85,624 | 0.15% | Shares |
| BlackRock, Inc. | $566,867 | 74,392 | 0.13% | Shares |
| Jump Financial, LLC | $472,440 | 62,000 | 0.11% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $446,532 | 58,600 | 0.10% | Shares |
| BANK OF AMERICA CORP /DE/ | $409,072 | 53,684 | 0.10% | Shares |
| Avidity Partners Management LP | $334,160 | 43,853 | 0.08% | Shares |
| TD Asset Management Inc | $325,603 | 42,730 | 0.08% | Shares |
| Virtus Investment Advisers, LLC | $321,716 | 42,220 | 0.07% | Shares |
| VANGUARD GROUP INC | $227,401 | 18,163 | 0.05% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $213,238 | 27,984 | 0.05% | Shares |
| TWO SIGMA INVESTMENTS, LP | $201,816 | 26,485 | 0.05% | Shares |
| Rafferty Asset Management, LLC | $172,258 | 22,606 | 0.04% | Shares |
| CITIGROUP INC | $151,425 | 19,872 | 0.04% | Shares |
| Squarepoint Ops LLC | $149,824 | 19,662 | 0.03% | Shares |
| Vanguard Global Advisers, LLC | $138,402 | 18,163 | 0.03% | Shares |
| Schonfeld Strategic Advisors LLC | $87,659 | 11,504 | 0.02% | Shares |
| PROFUND ADVISORS LLC | $83,828 | 11,001 | 0.02% | Shares |
| AXQ CAPITAL, LP | $81,747 | 10,728 | 0.02% | Shares |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $20,115 | 2,626 | 0.00% | Shares |
| BARCLAYS PLC | $15,827 | 2,077 | 0.00% | Shares |
| Tower Research Capital LLC (TRC) | $12,924 | 1,696 | 0.00% | Shares |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $10,287 | 1,350 | 0.00% | Shares |
| Rockefeller Capital Management L.P. | $7,620 | 1,000 | 0.00% | Shares |
| Integrated Wealth Concepts LLC | $3,330 | 437 | 0.00% | Shares |
| MORGAN STANLEY | $2,286 | 300 | 0.00% | Shares |
| WELLS FARGO & COMPANY/MN | $2,286 | 300 | 0.00% | Shares |
| PRICE T ROWE ASSOCIATES INC /MD/ | $2,286 | 300,000 | 0.00% | Shares |
| Quarry LP | $1,501 | 197 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $282 | 37 | 0.00% | Shares |
| Pacer Advisors, Inc. | $3 | 378 | 0.00% | Shares |
Company insiders 17 insiders · 5 officers · 10 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Pedro Beltran | President and CEO | July 1, 2026 F | 44,576 | 0 | 0 | $0 |
| Eli M. Wallace | Chief Executive Officer | Jan. 1, 2026 A | — | 0 | 0 | $0 |
| Idan Elmelech | COO & Principal Financial Ofcr | July 1, 2026 F | 14,495 | 0 | 0 | $0 |
| Yong Ben | Chief Med & Dev Officer | July 1, 2026 F | 44,576 | 0 | 0 | $0 |
| Marc Cobo | Principal Accounting Officer | July 1, 2026 F | 5,306 | 0 | 0 | $0 |
| Chen Bihua | Director | July 1, 2026 J | 6,083,221 | 0 | 0 | $0 |
| Peter F Lebowitz | Director | June 16, 2026 A | — | 0 | 0 | $0 |
| Raymond J. Kelleher | Director | June 16, 2026 A | — | 0 | 0 | $0 |
| Praveen P. Tipirneni | Director | June 16, 2026 A | — | 0 | 0 | $0 |
| Neil Kumar | Director | June 16, 2026 A | — | 0 | 0 | $0 |
| Jake Bauer | Director | June 16, 2026 A | — | 0 | 0 | $0 |
| Frank Mccormick | Director | June 16, 2026 A | — | 0 | 0 | $0 |
| Helix Holdings II LLC | Director | Feb. 8, 2025 J | 509,000 | 0 | 0 | $0 |
| Uneek Mehra | — | April 1, 2026 F | 22,806 | 0 | 0 | $0 |
| Albert A Holman III | — | Aug. 11, 2025 M | 30,000 | 0 | 0 | $0 |
| Mark C. Mckenna | — | Aug. 11, 2025 M | 30,000 | 0 | 0 | $0 |
| John P. Schmid | — | Aug. 11, 2025 M | 30,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Bihua Chen, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare Fund V, LP, Cormorant Private Healthcare GP V, LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Helix Holdings II LLC | July 6, 2026 | 22.32% | Amendment | — | SEC |
| BridgeBio Pharma LLC, BridgeBio Pharma, Inc. | Aug. 18, 2025 | 17.50% | Initial filing | — | SEC |
| Helix Holdings II LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Bihua Chen ×3 filings | Aug. 13, 2025 | 22.60% | Amendment | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| CANC · Tema ETF Trust | 0.48% | 93,339 NS | May 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.03% | 316,264 SH | Aug. 8, 2026 | Daily |
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 227,258 NS | May 31, 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 27,500 NS | May 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 549,132 SH | Aug. 8, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,422,900 SH | Aug. 8, 2026 | Daily |